1
aaron alls
Aaron Alls, Joseph Beck, Bruce W Farber: Gusseted torsion system for an open frame vehicle. Kelly Lowry & Kelley, August 13, 2009: US20090200836-A1

A gusseted torsion system minimizes torsional deflection in an open frame vehicle having a generally U-shaped frame with two generally parallel beams. The gusseted torsion system includes cross members extending between the parallel beams and gussets adjacent each end of the cross members. The gusse ...


2
aaron alls
Bruce W Farber, Aaron Alls, Joseph Beck: Slider scissor lift for a vehicle operator console. Kelly Lowry & Kelley, August 13, 2009: US20090200117-A1

An improved slider scissor lift results in forward or backward movement of a raised work platform. The forward or backward movement is achieved by positioning upper pins and sliders oppositely from lower pins and sliders. This oppositely pinned configuration results in an operation whereby the base ...


3
Erwin Meinders
Erwin Rinaldo Meinders, Rolf Antonie Loch: Master substrate and method of manufacturing a high-density relief structure. Koninklijke Philips Electronics, Muncy Geissler Olds & Lowe PLLC, August 13, 2009: US20090201793-A1

The present invention relates to a recording stack for obtaining a high-density relief structure, comprising: a first recording layer (10) on top of a second recording layer (12), the recording layers being supported by a substrate layer (14), wherein, upon projecting light on the recording layers, ...


4
Livak Kenneth J, Unger Marc: Dynamic array assay methods. Fluidigm Corporation, Livak Kenneth J, Unger Marc, TIGLIO Andrea Det al, August 13, 2009: WO/2009/100449 (73 worldwide citation)

High throughput methods are used that combine the features of using a matrix-type microfluidic device, labeled nucleic acid probes, and homogenous assays to detect and/or quantify nucleic acid analytes. The high throughput methods are capable of detecting nucleic acid analyes with high PCR and probe ...


5
Calvosa Giuseppe, Bartalesi Raphael, Tenucci Miria: Interspinous vertebral distractor for percutaneous implantation. Calvosa Giuseppe, Bartalesi Raphael, Tenucci Miria, PAPA Elisabettaet al, August 13, 2009: WO/2009/098536 (65 worldwide citation)

Interspinous distractor for percutaneous implantation comprising a central body (10) and two couples of stabilizers (14a,14b;14c,14d), hinged at the end of the body (10) in order to rotate from a closed position, which assists the percutaneous implantation of the distractor, to a spread apart positi ...


6

7

8
Babu Suresh R, Wada Yumiko, Shen Jack, Nguyen Nhung: Topical formulations for the treatment of psoriasis. Synta Pharmaceuticals, Babu Suresh R, Wada Yumiko, Shen Jack, Nguyen Nhung, HSI Jeffrey Det al, August 13, 2009: WO/2009/100406 (51 worldwide citation)

The invention relates to a topical composition and a method for treating psoriasis. The topical composisition comprises one or more compound that inhibits the production of IL- 12 and IL-23.


9
Skog Johan, Breakefield Xandra O, Brown Dennis, Miranda Kevin C, Russo Leileata M: Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions. The General Hospital Corporation, Skog Johan, Breakefield Xandra O, Brown Dennis, Miranda Kevin C, Russo Leileata M, RESNICK David, August 13, 2009: WO/2009/100029 (50 worldwide citation)

The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a' subject by detecting a biomarker in microvesicles isolated from a biological, sample from the subject. Moreover, disclosed subject mat ...


10
Dimarchi Richard D, de Arnab: Ester-based peptide prodrugs. Indiana University Research And Technology Corporation, Dimarchi Richard D, de Arnab, ADDISON Bradford G, August 13, 2009: WO/2009/099763 (49 worldwide citation)

Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., ...